drugset / Trial / NCT02309892
A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC
NaSequentialOpen-labelTreatment
Summary
The primary purpose of this research study is to evaluate how safe, how well tolerated and how effective a range of doses of L-DOS47 in combination with standard doublet therapy of pemetrexed/carboplatin in patients with Stage IV (TNM M1a and M1b) recurrent or metastatic non-squamous Non-Small Cell Lung Cancer.
Timeline
- Start
- 2015-04-20
- Primary completion
- 2019-08-19
- Completion
- 2019-09-20
Outcome
Outcome not reported
Stopped (Enrollment): “Slow enrolment - standard of care evolved over the duration of the study such that treatment regimen employed in the study was no longer current standard of care for first line resulting in recruitment challenges.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | L-DOS47 | Other / unclassified | 0.59 ug/kg | — |
| Subject | L-DOS47 | Other / unclassified | 0.78 ug/kg | — |
| Subject | L-DOS47 | Other / unclassified | 1.5 ug/kg | — |
| Subject | L-DOS47 | Other / unclassified | 3 ug/kg | — |
| Subject | L-DOS47 | Other / unclassified | 6 ug/kg | — |
| Subject | L-DOS47 | Other / unclassified | 9 ug/kg | — |
| Subject | L-DOS47 | Other / unclassified | 12 ug/kg | — |